These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11175726)

  • 1. Protein solubility and folding monitored in vivo by structural complementation of a genetic marker protein.
    Wigley WC; Stidham RD; Smith NM; Hunt JF; Thomas PJ
    Nat Biotechnol; 2001 Feb; 19(2):131-6. PubMed ID: 11175726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutagenesis of the central hydrophobic cluster in Abeta42 Alzheimer's peptide. Side-chain properties correlate with aggregation propensities.
    de Groot NS; Aviles FX; Vendrell J; Ventura S
    FEBS J; 2006 Feb; 273(3):658-68. PubMed ID: 16420488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probing the alpha-complementing domain of E. coli beta-galactosidase with use of an insertional pentapeptide mutagenesis strategy based on Mu in vitro DNA transposition.
    Poussu E; Vihinen M; Paulin L; Savilahti H
    Proteins; 2004 Mar; 54(4):681-92. PubMed ID: 14997564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Membrane docking of an aggregation-prone protein improves its solubilization.
    Tagourti J; Malki A; Kern R; d'Alençon E; Richarme G
    Gene; 2008 Dec; 426(1-2):32-8. PubMed ID: 18809475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo and in vitro protein solubility assays using split GFP.
    Cabantous S; Waldo GS
    Nat Methods; 2006 Oct; 3(10):845-54. PubMed ID: 16990817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-native interhelical hydrogen bonds in the cystic fibrosis transmembrane conductance regulator domain modulated by polar mutations.
    Choi MY; Cardarelli L; Therien AG; Deber CM
    Biochemistry; 2004 Jun; 43(25):8077-83. PubMed ID: 15209503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the extracellular loop in the folding of a CFTR transmembrane helical hairpin.
    Wehbi H; Rath A; Glibowicka M; Deber CM
    Biochemistry; 2007 Jun; 46(24):7099-106. PubMed ID: 17516627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing Alzheimer amyloid peptide aggregation using a cell-free fluorescent protein refolding method.
    Arslan PE; Chakrabartty A
    Biochem Cell Biol; 2009 Aug; 87(4):631-9. PubMed ID: 19767826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Misfolding of the cystic fibrosis transmembrane conductance regulator and disease.
    Cheung JC; Deber CM
    Biochemistry; 2008 Feb; 47(6):1465-73. PubMed ID: 18193900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and purification of a recombinant peptide from the Alzheimer's beta-amyloid protein for solid-state NMR.
    Sharpe S; Yau WM; Tycko R
    Protein Expr Purif; 2005 Jul; 42(1):200-10. PubMed ID: 15939307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Base treatment corrects defects due to misfolding of mutant cystic fibrosis transmembrane conductance regulator.
    Namkung W; Kim KH; Lee MG
    Gastroenterology; 2005 Dec; 129(6):1979-90. PubMed ID: 16344066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.
    Meli G; Visintin M; Cannistraci I; Cattaneo A
    J Mol Biol; 2009 Apr; 387(3):584-606. PubMed ID: 19361429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations that reduce aggregation of the Alzheimer's Abeta42 peptide: an unbiased search for the sequence determinants of Abeta amyloidogenesis.
    Wurth C; Guimard NK; Hecht MH
    J Mol Biol; 2002 Jun; 319(5):1279-90. PubMed ID: 12079364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic selection for protein solubility enabled by the folding quality control feature of the twin-arginine translocation pathway.
    Fisher AC; Kim W; DeLisa MP
    Protein Sci; 2006 Mar; 15(3):449-58. PubMed ID: 16452624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simple in vivo assay for increased protein solubility.
    Maxwell KL; Mittermaier AK; Forman-Kay JD; Davidson AR
    Protein Sci; 1999 Sep; 8(9):1908-11. PubMed ID: 10493593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Following nature's anti-amyloid strategy.
    Lansbury PT
    Nat Biotechnol; 2001 Feb; 19(2):112-3. PubMed ID: 11175720
    [No Abstract]   [Full Text] [Related]  

  • 17. Structural characterization of a soluble amyloid beta-peptide oligomer.
    Yu L; Edalji R; Harlan JE; Holzman TF; Lopez AP; Labkovsky B; Hillen H; Barghorn S; Ebert U; Richardson PL; Miesbauer L; Solomon L; Bartley D; Walter K; Johnson RW; Hajduk PJ; Olejniczak ET
    Biochemistry; 2009 Mar; 48(9):1870-7. PubMed ID: 19216516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A portable allosteric mechanism.
    Gryczynski U; Schleif R
    Proteins; 2004 Oct; 57(1):9-11. PubMed ID: 15326589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation of highly toxic soluble amyloid beta oligomers by the molecular chaperone prefoldin.
    Sakono M; Zako T; Ueda H; Yohda M; Maeda M
    FEBS J; 2008 Dec; 275(23):5982-93. PubMed ID: 19021772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing protein aggregation by its hyper-acidic fusion cognates in Escherichia coli.
    Zou Z; Fan Y; Zhang C
    Protein Expr Purif; 2011 Nov; 80(1):138-44. PubMed ID: 21704170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.